Intellia Therapeutics (NTLA) Net Equity Issued and Repurchased (2015 - 2026)

Intellia Therapeutics (NTLA) has 9 years of Net Equity Issued and Repurchased data on file, last reported at $750.0 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $750.0 million in Q1 2026; TTM through Mar 2026 was $878.2 million, a 638.8% increase from a year earlier, with the FY2025 full-year figure at $128.2 million, down 27.54% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $750.0 million, up from $114.5 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for NTLA reached as high as $750.0 million in Q1 2026 and fell as low as -$361.1 million in Q2 2022.
• Historically, Net Equity Issued and Repurchased has averaged $112.5 million across 5 years, with a median of $47.2 million in 2024.
• Across the five-year window, Net Equity Issued and Repurchased plunged 99.63% in 2023 and jumped 3858.66% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $337.9 million in 2022, then slumped by 69.33% to $103.6 million in 2023, then tumbled by 98.07% to $2.0 million in 2024, then jumped by 5626.61% to $114.5 million in 2025, then surged by 555.16% to $750.0 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $750.0 million in Q1 2026, $114.5 million in Q3 2025, and $13.7 million in Q2 2025.